Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. - Ganan-Gomez I; Yang H; Ma F; Montalban-Bravo G; Thongon N; Marchica V; Richard-Carpentier G; Chien K; Manyam G; Wang F; Alfonso A; Chen S; et al. (Nature medicine, 2022)